RMIT-led research advances dry mRNA vaccine patches to ease global distribution

A team of researchers at RMIT University, working alongside scientists from MIT and Harvard Medical School, has mapped out the conditions needed to keep mRNA vaccines stable when dried into tiny patches that dissolve against the skin. The work, published in Advanced Functional Materials, tackles one of the thorniest problems in global vaccine distribution: the need to keep most mRNA vaccines frozen during transport and storage, a logistical burden that adds cost, complexity, and often fails entirely in places without reliable refrigeration.

The patches themselves are elegant in concept. Rather than a needle, they use hundreds of microscopic projections to deliver vaccine directly through the skin, like a dissolving sticker. But the real innovation here is what happens before that moment of use. The researchers wanted to understand what occurs to the lipid nanoparticles—the fatty spheres that ferry mRNA into cells—when they're dried into the patch material and then rehydrated on the skin. Using advanced imaging and X-ray analysis, they watched these particles through each stage: intact, drying, dried, and rehydrated. What they found was that the particles' structure and potency depend heavily on two things: how the nanoparticles themselves are designed, and how much polymer is mixed into the patch material.

Dr Brendan Dyett, the lead author, framed the stakes plainly. Most mRNA vaccines demand storage at extremely low temperatures, which means expensive freezers, specialized transport containers, and trained personnel to manage the cold chain. That infrastructure doesn't exist everywhere it's needed. His team's work explains why some formulations hold up better than others through the drying and rehydration cycle—knowledge that can now guide the design of patches that actually work when they reach clinics in remote areas or countries with limited cold-storage capacity.

The human dimension of this research is substantial. According to the World Health Organization and UNICEF, 14.3 million children worldwide received no vaccines at all in 2024. That number reflects not just disease burden but also the practical failure of distribution systems. A vaccine patch that survives at room temperature, that requires no special handling, that can be applied without trained medical staff—such a tool could shift access fundamentally. It's the kind of technology that works not because it's more sophisticated, but because it's simpler to use where it matters most.

Calum Drummond, a distinguished professor at RMIT, articulated the longer vision. The goal isn't just to make vaccines easier to distribute. It's to build a foundation for mRNA-based medicines more broadly—treatments for cancer, rare genetic diseases, personalized therapies—that could be deployed in places currently locked out of those possibilities by cold-chain constraints. The research team is now moving toward the next phase: further refining the nanoparticle and patch formulations, testing immune responses in living systems, and exploring whether the same principles could extend to other mRNA therapeutics beyond vaccines.

This is incremental science in the best sense. It's not a breakthrough that solves the problem overnight. But it's the kind of careful, collaborative work—combining RMIT's materials expertise with MIT's delivery technology and Harvard's immunology—that turns a theoretical possibility into practical guidance. The patches still need optimization. The immune responses still need validation. But the path forward is now clearer, and the stakes for getting it right are measured in millions of children who might finally have access to protection that currently remains out of reach.